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Traumatic Brain Injury (TBI) is a global health concern.The majority ofTBI’s are mild, yet our
ability to diagnose and treat mild traumatic brain injury (mTBI) is lacking. This deficiency
results from a variety of issues including the difficulty in interpreting ambiguous clinically
presented symptoms, and ineffective imaging techniques.Thus, researchers have begun to
explore cellular and molecular based approaches to improve both diagnosis and prognosis.
This has been met with a variety of challenges, including difficulty in relating biological mark-
ers to current clinical symptoms, and overcoming our lack of fundamental understanding
of the pathophysiology of mTBI. However, recent adoption of high throughput technolo-
gies and a change in focus from the identification of single to multiple markers has given
just optimism to mTBI research. The purpose of this review is to highlight a number of
current experimental peripheral blood biomarkers of mTBI, as well as comment on the
issues surrounding their clinical application and utility.
Keywords: peripheral blood, diagnostic markers, prognostic markers, pathophysiology, biological mechanisms,
high throughput, post-concussion syndrome, chronic traumatic encephalopathy
INTRODUCTION
Traumatic brain injury (TBI) affects up to 10 million people glob-
ally (Hyder et al., 2007). Mild traumatic brain injury (mTBI)
accounts for between 70 and 90% of all TBI cases, and has an
estimated incidence rate of 653/100,000 people in Ontario alone
(Ryu et al., 2009). mTBI has gained considerable notoriety during
the past decade of conflict in Afghanistan and Iraq as a common
source of morbidity from these wars. An estimated 10–20% of all
veterans of these conflicts sustain mTBI, with blast injuries being
the leading cause (Schneiderman et al., 2008; Kelly et al., 2012;
Shively and Perl, 2012). Yet, mTBI is proportionally understudied
compared to moderate and severe injury (Papa et al., 2008).
The underlying pathophysiology of mTBI remains undeter-
mined, and as a result there are currently no efficient diag-
nostic, prognostic, or therapeutic strategies available clinically.
Researchers have begun to investigate mTBI at the cellular and
molecular level, as shortcomings in current brain imaging tech-
niques and flawed clinical diagnostic approaches have increased
the appeal of utilizing the peripheral blood to identify immune
and damage related signaling between the brain and the periph-
ery. Specifically, the goal of this approach is to uncover either a
single marker or panel of markers to aid in early detection and
diagnosis, as well as to predict patient outcomes. Furthermore,
this method may help elucidate underlying biological mechanisms
and provide greater insight into therapeutic strategies. However,
the utility of such markers needs to be determined in the exper-
imental phase through careful evaluation against specific clinical
questions, including: whether/how they directly relate to dis-
ease mechanisms, prognosis, diagnosis, and the monitoring of
therapeutic inventions. This validation will facilitate a positive
transition within the “bench to bedside” process.
The determinants and modifiers of the clinical entity of concus-
sion, mTBI, and post-concussion syndrome (PCS) include several
factors such as environmental, psychosocial, and co-morbidities
among others. These factors may be operative before and/or after
trauma. The scope of this review is narrowly focused on the biolog-
ical factors of presumed loss of cell integrity that can be detected
using signature biochemical biomarker patterns in human periph-
eral blood, in terms of their specific utility and clinical relevance in
relating to pathophysiology, diagnosis, and prognosis. Biomarker
categorization will be based on a stratification originally put forth
by the Biomarkers Definition Working Group (BDWG) (Biomark-
ers Definitions Working Group, 2001), and serve to aid in the
guided development of translating important laboratory findings
into meaningful clinical practice.
mTBI DEFINITION AND TERMINOLOGY
In order to assess and treat mTBI clinically, a clear definition is
necessary. In view of this, clinicians and researchers have histori-
cally struggled to agree on a singular mTBI definition and accepted
terminology (Moser et al., 2007; Ruff et al., 2009; Marshall et al.,
2012). This disagreement may stem from a variety of issues includ-
ing the heterogeneity in both trauma mechanism and symptom
presentation, and the difficulty in detecting signs and symptoms of
injury (Greenwald et al., 2012). In addition, there are disputes over
the use of the term mTBI as opposed to concussion; it is unclear if
these terms can be used interchangeably, or if there is a difference
in the underlying definition (Greenwald et al., 2012; Jeter et al.,
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2012). It has been suggested that an mTBI that occurs in sports
is typically referred to as a concussion (Moser et al., 2007). In an
attempt at clarity and unification, a definition has been put forth
by the American Congress of Rehabilitation Medicine (ACRM)
that is endorsed by both the Centre of Disease Control and Pre-
vention (CDC) and the World Health Organization (WHO). In
summary, the ACRM defines an mTBI as:
“A traumatically induced physiological disruption of brain
function, as manifested by at least one of the following. . .loss
of consciousness. . .any loss of memory for events immedi-
ately before or after the event. . .focal neurologic deficit that
may or may not be transient, but where the severity of the
injury does not exceed the following: loss of consciousness of
approximately 30 min or less after 30 min, an initial Glasgow
Coma Scale score of 13–15 and post-traumatic amnesia not
greater than 24 h” (Greenwald et al., 2012).
PERIPHERAL BLOOD AS A SOURCE FOR mTBI BIOMARKERS
Using peripheral blood for mTBI biomarker discovery potentially
addresses a number of clinical concerns, such as current diagnos-
tic, prognostic, and treatment approach pitfalls, the difficulty in
creating representative animal models of human mTBI, and the
inability to conduct biological studies on patients at the primary
site of injury. For example, diagnosis and prognosis in moderate
and severe TBI using conventional imaging techniques is infor-
mative (Shenton et al., 2012), but these techniques fail to detect
the majority of mild brain injuries and provide little or no patho-
physiological information related to injury mechanism (Papa et al.,
2008; Bettermann and Slocomb,2012). Furthermore,animal mod-
els of human mTBI, which have largely focused on the use of
rodents, have been met with little success. This is due to a number
of factors, such as the heterogeneity of the human clinical popula-
tion from which it mimics, and the anatomical differences between
the human and rodent brain (Marklund and Hillered, 2011).
Lastly, the use of a biological correlate at or near the site of injury,
such as the Cerebrospinal Fluid (CSF) is potentially advantageous
due to its proximity to the brain and involvement in the central
nervous system (CNS). However, the acquisition of CSF fluid is
a relatively invasive procedure. By comparison, acquiring a blood
sample from a patient population is more accepted in clinical prac-
tice, and can provide substantial information relating to specific
neurological injury processes within the brain, the blood brain
barrier (BBB), and neuroendocrine-immune signaling processes
between the CNS and periphery.
BIOMARKERS OF mTBI DIAGNOSIS
Ideally, a diagnostic biomarker should indicate the presence or
absence of disease/injury, and more specifically, should be able
to stage or classify its severity (Biomarkers Definitions Working
Group, 2001). No clinically accepted TBI peripheral blood bio-
markers currently exist (Bettermann and Slocomb, 2012). The
spectrum of TBI is presently diagnosed and stratified through
the Glasgow Coma Scale (GCS) rating system alongside pre-
sentation, neurological examination, and CT imaging (Sharma
and Laskowitz, 2012). While the GCS can be effective in assess-
ing neurocognitive state, and offers some prognostic information
regarding patient outcome, it tells us little about the physiological
source of these symptoms, and can be confounded by polytrauma,
alcohol, and other drug use (Papa, 2012). In addition, clinical
CT imaging often fails to detect moderate and mild TBI, causes
potential exposure to harmful radiation, and is a relatively costly
procedure (Bettermann and Slocomb, 2012).
Diagnosing mTBI through a blood-based test may circumvent
the pitfalls of the current clinical diagnostic approach, potentially
offering a specific and sensitive evaluation of presented neuro-
logical deficit that is based on objective, quantifiable biological
changes directly related to trauma physiology (Topolovec-Vranic
et al., 2011). However, this approach is confounded by a vari-
ety of factors, including a poor understanding of the underlying
biological mechanisms of mTBI, as well as the difficulty in link-
ing blood-based protein markers to a range of dynamic clinical
symptoms that are difficult to objectively assess. Moreover, in
specific populations such as military personnel, the relationship
between combat-related mTBI and residual mTBI symptoms,
post-traumatic stress disorder (PTSD) symptoms, and neurocog-
nitive deficits remains unclear (Brenner, 2011; Miller, 2011). TBI
occurrence and severity are difficult to ascertain in this popula-
tion because of retrospective bias in determining relevant clinical
variables, such as whether there was loss of consciousness or post-
traumatic amnesia (Schneiderman et al., 2008; Kelly et al., 2012;
Shively and Perl, 2012).
Numerous markers have been evaluated on their ability to
diagnose mTBI, with modest success. The most widely studied
marker in brain injury is Serum protein 100B (s100B), a low affin-
ity calcium binding protein primarily expressed in glial cells and
Schwann cells (Persson et al., 1987). s100B is a highly sensitive
protein that can be found in both the CSF and blood within 6 h
of mTBI (de Kruijk et al., 2001; Berger et al., 2002; Giacoppo
et al., 2012). However, s100B has poor specificity, as it can be
extracranially derived from various cell types elsewhere in the
body (Bettermann and Slocomb, 2012). Furthermore, the func-
tion of this marker itself is not itself fully understood (Giacoppo
et al., 2012), and thus should not be considered as a stand-alone
marker for mTBI diagnosis. Similar conclusions have also been
made about Neuron Specific Enolase (NSE), a neuronal damage
marker. NSE was assumed to have high specificity to the brain,
but was found be released into the serum as a result of hemolysis
(Giacoppo et al., 2012; Papa, 2012; Žurek and Fedora, 2012), limit-
ing its accuracy as a predictor of brain injury. Possibly more brain
specific than NSE, however, is Ubiquitin Protein Hydrolase – 1
(UCH-L1), a marker of neuronal damage linked to TBI (Berger
et al., 2012). UCH-L1 can be located in the serum of patients
within 4 h of injury (Berger et al., 2012), but has yet to correlate
with mTBI (Berger et al., 2012). Conversely, Myelin Basic Protein
(MBP) measures axonal damage, and unlike s100B and NSE, has
high brain specificity, but suffers from a delayed introduction into
the blood stream (24–72 h post-injury) (Giacoppo et al., 2012).
Despite the limited success of various diagnostic mTBI bio-
markers to date, current research provides reason for optimism.
Recent work by Papa et al. (2012) has identified Glial Fibrillary
Acidic Protein Breakdown Products (GFAP – BDP) elevated in
the serum of mild and moderate TBI patients within a few hours
of injury. Importantly, these increases were also correlated with
GCS ratings, CT lesions, and neurosurgical interventions (Papa
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et al., 2012). Furthermore, GFAP itself appears to show high speci-
ficity to brain tissue, as multi-trauma does not affect its serum
levels (Pelinka et al., 2005). Although caution must be taken in
the interpretation of all correlative analyses, these findings are
promising.
While markers such as GFAP and UCHL-1 measure astro-
cytic and neuronal damage, respectively, an important issue is
raised regarding“proof of concept.”The pathophysiological mech-
anism(s) of trauma-induced injury in mTBI is unclear, and any
single marker representing what may only be one “piece of the
puzzle” has to be interpreted with caution. mTBI may encompass
both neuronal and glial cell injury, with possible damage specific to
axonal structures (Johnson et al., 2012) (see Table 1 for a summary
of blood biomarkers in mTBI). In view of this, multiple markers
used to assess the spectrum of brain tissue injuries that are mech-
anistically correlated with clinical symptoms would likely increase
diagnostic accuracy. Furthermore, specific symptoms (e.g., loss of
consciousness, amnesia) and types of trauma (e.g., focal versus,
diffuse, direct head impact versus acceleration/deceleration injury
not specific to the head) may need to be examined separately with
greater scrutiny in order to create more direct connections between
specific biological markers observed in the blood after injury and
their precise underlying etiology.
BIOMARKERS OF mTBI PROGNOSIS
A prognostic biomarker is used to predict the clinical outcome
of a disease or injury (Biomarkers Definitions Working Group,
2001; Petzold, 2007) and can be useful in guiding treatment strate-
gies (Petzold, 2007). In mTBI, prognostic biomarkers generally
have a twofold purpose: (1) to predict recovery; (2) to stratify
risk for specific secondary pathological outcomes, such as PCS
and chronic traumatic encephalopathy (CTE) (Bruns and Jagoda,
2009). However, prognostic markers may also have more precise
predictive utility, such as aiding in the clinical decision to image
patients (Biberthaler et al., 2006). Unfortunately, there are cur-
rently no accurate prognostic biomarkers of mTBI outcome, and
more specifically, in risk stratification for the development of PCS
and CTE. This problem is further compounded by the lack of
diagnostic markers for CTE and PCS themselves (Lakhan and
Kirchgessner, 2012).
The chronic affects of mTBI have received increasing media
attention due to its impact on affected athletes and military per-
sonnel (Cancelliere et al., 2012). Among those who have had an
mTBI, 50% will continue to experience cognitive, neurological,
and behavioral symptoms such as headache, difficulty concentrat-
ing, anxiety, and depression (Begaz et al., 2006). This percentage
drops to around 15% at the 1-year mark (Begaz et al., 2006), while
some may continue to experience symptoms for years post-injury
(NIH, 1999). This condition is known as PCS, and to date, little
is known about its pathophysiological etiology (Nygren-de Bous-
sard et al., 2004). Furthermore, chronic mTBI patients may also be
at risk for CTE. CTE was originally identified over 80 years ago in
“punch drunk” boxers, and presents as a neurodegenerative con-
dition that worsens with age, quite often resulting in dementia,
depression, memory loss, and even suicide. CTE may occur as a
result of multiple brain injuries; 17% of those with repetitive head
injuries go on to develop this syndrome (McKee et al., 2009).
To date, analysis of prognostic mTBI markers have been corre-
lated to clinical decisions to image,as well as various clinical indices
of recovery such as return to work (RTW) and the Glasgow Out-
come Scale (GOS) (Bazarian et al., 2006; Beers et al., 2007; Metting
et al., 2012). It was originally believed that s100B would be a use-
ful clinical aid in predicting recovery and lowering the number of
ill-advised CT scans (Ingebrigtsen and Romner, 1996). Unfortu-
nately, recent assessments of this marker have revealed it is a poor
predictor of intracranial risk (Morochovic et al., 2009), early neu-
rological outcome (Piazza et al., 2007; Morochovic et al., 2009),
and long-term post-concussion symptoms (Bazarian et al., 2006).
In addition, increased levels of serum s100B have been noted in
patients who have made a complete neurological recovery (Piazza
et al., 2007). s100B has also been outperformed by GFAP in pre-
dicting long-term outcome (6 months), as reflected by the Glasgow
Outcome Score Extended (GOSE) and RTW assessment (Metting
et al., 2012). However, the authors of this study concluded that
GFAP was still a weak overall predictor of outcome in mTBI (Met-
ting et al., 2012). Also, NSE serum levels 1 month post mTBI are
not correlated to outcome as reflected by the GOS (Meric et al.,
2010), and the Tau protein has not been shown to correlate to PCS
at 3 months (Ma et al., 2008) (see Table 1). Yet, the interpreta-
tion of these results must be approached cautiously, particularly
in correlating mTBI recovery to assessments such as the GOSE and
RTW. While possibly indicative of recovery, these correlates pro-
vide no objective and reliable pathophysiological determination.
For example, it is quite possible that a patient suffering with PCS
may RTW while not completely recovered, and conversely, some
patients may have recovered well before they RTW. The GOSE
and RTW assessments contain fairly ambiguous groupings such
as “moderately disabled,”“good recovery,” and “previous work not
resumed, but working on a lower level” (Metting et al., 2012). The
utility of these types of scales, which are based on limited clinical
symptom assessment, should be questioned, as the potential for
subjective interpretation is high.
A greater number of longitudinal, multi-marker studies corre-
lated with specific secondary symptoms (e.g., headaches, nausea,
anxiety) may provide a useful kinetic background to identify can-
didate prognostic biomarkers. Beers et al. (2007), provide a useful
framework through their study design, assessing multiple markers
at multiple points in the acute period after trauma and at 6 months.
Metting et al. (2012) also used a multi-marker approach, assess-
ing GFAP and s100B as outcome markers in mTBI. More studies
following this approach would be of use. Furthermore, diagnos-
ing PCS and CTE still remain a challenge for clinicians, and until
this is rectified, it will remain difficult to accurately predict patient
outcome.
BIOMARKERS OF mTBI PATHOPHYSIOLOGY
The fundamental pathophysiology of injury in mTBI is not under-
stood, making it difficult to identify clinically functional biomark-
ers. Still, while many well-studied biomarkers have been criticized
for their inability to suffice as stand-alone indicators of injury
presence and outcome (Rothermundt et al., 2003; Giacoppo et al.,
2012; Papa, 2012), investigating these markers has provided us
with pivotal insight into the pathophysiology of mTBI. For exam-
ple, clinically presented symptom clusters of mTBI are thought to
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Table 1 | Selected peripheral blood biomarkers of mTBI.
Marker Biological roles Diagnostic Prognostic Injury mechanism Reference
s100B Calcium binding protein
found in astrocytes and
some neuronal cells
Lacks specificity,
elevated levels found in
the serum of
multi-trauma patients
Poorly related to
outcome as measured
by return to work (RTW)
Suggests astrocyte
damage/activation as a
cellular sequelae to
primary insult, as well
as possible BBB
disruption
Bazarian et al. (2006),
Biberthaler et al. (2006),
Naeimi et al. (2006), de
Kruijk et al. (2001), Metting
et al. (2012), Nygren-de
Boussard et al. (2004)
Found elevated in
serum acutely post
mTBI
Some validity for
diagnosis of intracranial
lesions (IL)
Even highly elevated
levels have been shown
full recovery
NSE Glycolytic enzyme,
specific to the
cytoplasm of neurons
Lacks sensitivity, and
specificity; elevated
levels found in blood
resulting from
hemolysis
Poor correlation
between serum levels
and GOS
Suggests acute
neuronal damage
Meric et al. (2010), Naeimi
et al. (2006), Berger et al.
(2007), de Kruijk et al. (2001)
Elevated post mTBI
GFAP/GFAP
BDP
Protein found in glial
cells, major part of the
astroglial skeleton
Promising, BDPs have
high specificity and
sensitivity
Poor predictor of RTW
or GOSE
Suggests astrocyte
damage, possible BBB
disruption
Papa et al. (2012), Metting
et al. (2012)
Elevated within 1-h post
mTBI
MBP One of two most
abundant CNS proteins
found in myelin
Detection of serum
elevations may take up
to 2–3 days, making it
temporally unfavorable
Elevated serum levels
may be related to poor
outcome
Suggests structural
axonal damage
Beers et al. (2007), Berger
et al. (2005)
Elevated in serum post
mTBI
Tau Microtubule associated
proteins located in CNS
axons
Correlated with mTBI Poor outcome predictor
using 3-months PCS
assessment as well as
RPCQ
Suggests
hyperphosphorylation
resulting in formation of
CNS tangles
“tauopathy”
Guzel et al. (2010), Ma et al.
(2008), Bazarian et al.
(2006), Bulut et al. (2006),
Small et al. (2013)
Found elevated in the
serum within 6 h of
mTBI
Unable to identify
patients with IL found
on CT scans
UCH-L1 Cytoplasmic protein
found specifically in
neurons
Not associated with
pediatric mTBI
N/A Suggests neuronal loss
and disruption of the
BBB
Berger et al. (2012)
SBDP145 One of the all-spectrin
breakdown products,
found in presynaptic
terminals and axons
Not associated with
pediatric mTBI
N/A Suggests cell necrosis Berger et al. (2012)
be associated with neuronal (de Kruijk et al., 2001) and glial cell
damage/activation (Pelinka et al., 2004; Metting et al., 2012), often
specifically pertaining to axon structures (Bulut et al., 2006; Berger
et al., 2007; Guzel et al., 2010), developing into what has become
known as diffuse axonal injury (DAI) (Johnson et al., 2012). These
developments, as well as our present understanding of secondary
injury in mTBI are based on both experimental studies, and a
large existing body of research on moderate and severe TBI. From
this it has been suggested that secondary injury results from a
maladaptive healing response that amplifies the damage incurred
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from primary injury. This is accomplished in a complex, multi-
faceted nature, involving a variety of biochemical cascades related
to a disruption in energy metabolism, protein synthesis and degra-
dation, and dysfunction at the level of neural synapse (Greve and
Zink, 2009; Cederberg and Siesjö, 2010; Jaerve and Müller, 2012;
Johnson et al., 2012; Kan et al., 2012). However, studies on the
biological sequelae resulting from the primary insult in mTBI are
still relatively scarce.
Very few potential markers related to the advent of secondary
injury have been assessed. Among these is SBD145, a cleavage
product of αII-spectrin that is indicative of cell necrosis (Berger
et al., 2012). However, in a single study assessing this marker in
mTBI patients, no correlation between blood levels of SBD145 and
predictive outcome in pediatric mTBI was found (Berger et al.,
2012). The Tau protein has also been implicated in mTBI sec-
ondary injury, and has been found elevated in the serum of mTBI
patients (Guzel et al., 2010). The term “tauopathy” has been asso-
ciated with other neurological disorders such as Alzheimer’s and
Parkinson’s disease, and is thought to be involved in the etiology
of CTE (McKee et al., 2009). Tauopathy refers to the hyperphos-
phorylation of the Tau protein, causing biochemical alterations
which lead to the formation of axonal tangles, ending in disrup-
tion of neuronal communication (McKee et al., 2009; Guzel et al.,
2010). In view of this, Small et al. (2013) recently demonstrated
increased Tau deposits in retired NFL players with histories of cog-
nitive and mood symptoms. Although this preliminary study was
constrained by a small sample size, it is the first report to date
to identify such findings in live humans at risk for CTE. Further
studies assessing this possible mechanism would help not only in
CTE pathology, but would provide pivotal information about the
degenerative processes occurring post mTBI.
There is strong evidence to support that TBI pathophysiol-
ogy involves systemic innate and adaptive immune responses
that are intricately involved in a communicative process between
the periphery and brain parenchyma (Morganti-Kossmann et al.,
2007; Cederberg and Siesjö, 2010; Giacoppo et al., 2012; Papa,
2012). In addition, recent experimental data in animals and
humans in TBI have uncovered immunoexcitotoxicity as a novel
pathological mechanism leading to CTE (Blaylock and Maroon,
2011). Thus, in parallel with the necessity of understanding the
molecular pathophysiology of cell damage, there is a need for
clinical studies in mTBI assessing markers of inflammation, in
particular, those involving the recruitment of immune cells into
both cellular and microvascular brain structures (Kochanek and
Hallenbeck, 1992; Clark et al., 1994).
SUMMARY/FUTURE DIRECTIONS
Considering the health related and economic impact of mTBI
(Dash et al., 2010; Giacoppo et al., 2012; Papa, 2012), an improved
understanding of this condition is urgent. The prospect of using
peripheral blood-based markers synergistically with current clini-
cal diagnostic and prognostic assessments of mTBI is favorable for
a variety of reasons: (1) it is more clinically accepted compared to
other invasive procedures; (2) it is cost effective; (3) it may quickly
and accurately provide specific information about the underlying
pathophysiology of mTBI, which clinicians can then use in the
diagnosis and formulation of treatment strategies.
Ultimately, the goal of biomarker research is to identify sur-
rogate markers as an adjunct or replacement for specific clinical
endpoints. By definition, the surrogate marker is one of achieve-
ment, as biomarkers are first considered “candidates” in hopes of
acquiring the surrogate rank. However, in order to identify mark-
ers that may achieve this status, an in depth understanding of
the cellular and molecular pathogenic mechanisms of mTBI is
required. This point cannot be overlooked in any facet of bio-
marker research. Our current understanding of both primary and
secondary mTBI pathology is poor, as is our understanding of PCS
and CTE. Future research, whether experimental or clinical, would
benefit by employing a more mechanistic based focus. Assessing
a panel of markers will likely improve diagnostic and prognostic
accuracy. Furthermore, in order to ensure proof of principle, spe-
cific mTBI symptoms need to be more directly linked to biological
findings to establish causation. It will remain difficult to iden-
tify the mechanistic underpinnings of mTBI if biological findings
are simply correlated to a cluster of symptoms. Controlling for
specific symptoms/outcomes through greater cohort stratification
may prove useful.
PROSPECTIVE TRANSLATIONAL TECHNIQUES
High throughput “OMICs” technologies will continue to be
invaluable moving forward with enhanced detection and char-
acterization of novel blood-borne biomolecules. The field of pro-
teomics shows great promise through its ability to characterize
entire cellular environments (“Top-down approach”) and iden-
tify novel proteins involved in pathological processes (“Bottom-up
approach”) (Colantonio and Chan, 2005). Wang et al. (2005) have
published a very informative review on proteomic based research
in TBI that captivates the essential importance and potential of
this technology to the field.
Assessing the peripheral immune system in mTBI may poten-
tially lead to invaluable information on the cause and/or con-
sequence of secondary injury. Although severely understudied
in mTBI, research in moderate and severe TBI has underlined
neuroinflammation as an important process in secondary injury
(Lenzlinger et al., 2001; Jaerve and Müller, 2012). In view of this,
flow cytometry is a high throughput immunological technique
with proven utility to elucidate pathological cell signaling path-
ways using human biological fluids, including whole blood, and
is also used as a clinical diagnostic tool (Laerum and Farsund,
1981). Studies assessing the mechanisms underlying secondary
injury in mTBI that incorporate conventional flow cytometry
and imaging cytometry may yield important advancements to
our understanding of both injury pathology and etiology of PCS
and CTE.
In moving forward, it will be important for mTBI research
to focus on elucidating pathophysiology. It would appear that
a single marker will not achieve this, and to date, the search
for biological indicators of mTBI has been met with lim-
ited success. However, there is much reason for optimism
with regard to the ultimate potential of blood-based biomark-
ers. Recent data on such markers as GFAP-SBP and Tau have
proved hopeful (Papa et al., 2012; Small et al., 2013). These
markers may provide pivotal information into the underlying
pathology behind mTBI and CTE respectively. Furthermore,
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advances in high throughput “OMICs” techniques such as mass
spectrometry and imaging cytometry provide real potential in
uncovering the biological mechanisms underlying mTBI and its
chronic sequelae. These techniques will no doubt be intrinsically
involved in the entire translational process of mTBI research,
from the elucidation of pathophysiological mechanisms to the
clinical implementation of validated diagnostic and prognostic
biomarkers.
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